Dawn M. Gencarelli
This meeting focused on the processes used by health plans and other payers to make decisions about which drugs to include on formularies. Building upon “Evidence-Based and Value-Based Formulary Guidelines,” an article by Peter J. Neumann that appeared in the January/February 2004 issue of Health Affairs, it examined the trend toward evidence- and value-based formulary guidelines and their implications for drug companies, health plans, state Medicaid programs, and consumers, particularly in light of the passage of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The session highlighted the state of Oregon’s experience in its development of an evidence-based Medicaid formulary.
Peter Neumann, ScD, Associate Professor of Policy and Decision Sciences, Harvard School of Public Health; Mark Gibson, Deputy Director, Center for Evidence Based Policy, Oregon Health and Science University; David Clark, Vice President, Pharmacy Benefits Management, The Regence Group/RegenceRx; Jean Paul Gagnon, PhD, Director, Public Policy, Aventis Pharmaceuticals Inc.; Gail Shearer, Director, Health Policy Analysis, Washington Office, Consumers Union